<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="137991">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02072681</url>
  </required_header>
  <id_info>
    <org_study_id>20120079</org_study_id>
    <nct_id>NCT02072681</nct_id>
  </id_info>
  <brief_title>Mild and Rapidly Improving Stroke Study</brief_title>
  <acronym>MaRISS</acronym>
  <official_title>Mild and Rapidly Improving Stroke Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Heart Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to determine the 90-day outcomes of mild and rapidly
      improving ischemic stroke.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">October 2016</completion_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <target_duration>3 Months</target_duration>
  <primary_outcome>
    <measure>Proportion of patients not independent at 90 days</measure>
    <time_frame>90 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary outcome measure is proportion of patients with a modified Rankin Scale of 2-6 at 90 days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with dependence or disability in activities of daily living at 90 days</measure>
    <time_frame>90 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Proportion of patients not independent in activities of daily living defined as a Barthel Index score &lt;95</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic intracranial hemorrhage due to Alteplase</measure>
    <time_frame>36 hours</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Amongst those that receive intravenous Alteplase, a secondary safety measure is the proportion of patients that develop neurologic worsening development of symptomatic intracerebral hemorrhage, defined as neurological deterioration that, in the judgment of the investigator, is related to intracranial hemorrhage confirmed by CT or MRI, within 36 hours of administration of Alteplase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients not independent at 30 days</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Proportion of patients with modified Rankin Scale 2-6 at 30 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life by the EuroQOL EQ-5D</measure>
    <time_frame>90 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>EuroQOL will be treated as a continuous measure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke disability by the Stroke-Impact Scale-16</measure>
    <time_frame>90 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>SIS-16 will be treated as a continuous measure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Independence with Activities of Daily Living by the Barthel Index</measure>
    <time_frame>90 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>BI will be treated as a continuous measure; pre specified analysis include proportion of patients with Barthel Index &lt;95</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">2650</enrollment>
  <condition>Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Mild and Rapidly Improving Ischemic Stroke</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with ischemic stroke defined clinically as mild and/or rapidly improving and
        confirmed by neuroimaging not to have a hemorrhagic stroke with symptom onset within 4.5
        hours.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Mild or rapidly improving ischemic stroke confirmed by neuroimaging

          -  Arrival to hospital within 4.5 hours of symptom onset

          -  Willing to provide consent

          -  Available for a telephone interview at 30 and 90 days

        Exclusion Criteria:

          -  Onset &gt;4.5 hours

          -  Unable to provide informed consent (patient or legally appointed representative

          -  Premorbid modified Rankin Scale &gt;1

          -  Unavailable by telephone for follow-up
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jose G Romano, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jose G Romano, MD</last_name>
    <phone>305-243-8018</phone>
    <email>jromano@med.miami.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Iszet Campo-Bustillo, MD, MPH</last_name>
    <phone>305-243-8018</phone>
    <email>icampo@med.miami.edu</email>
  </overall_contact_backup>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 24, 2014</lastchanged_date>
  <firstreceived_date>January 9, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Jose Romano, MD</investigator_full_name>
    <investigator_title>Professor of Clinical Neurology</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
